---
title: "Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285381535.md"
description: "Allogene Therapeutics, Inc., a clinical-stage biotechnology company (Nasdaq: ALLO) based in South San Francisco, has scheduled its release of the first quarter financial results for 2026 along with a business update on May 13, 2026. The announcement is set to occur after the market closes, followed by a live audio webcast and conference call at 2 p.m. PT/5 p.m. ET. Allogene focuses on developing allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease."
datetime: "2026-05-06T12:32:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285381535.md)
  - [en](https://longbridge.com/en/news/285381535.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285381535.md)
---

# Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

Allogene Therapeutics, Inc., a clinical-stage biotechnology company (Nasdaq: ALLO) based in South San Francisco, has scheduled its release of the first quarter financial results for 2026 along with a business update on May 13, 2026. The announcement is set to occur after the market closes, followed by a live audio webcast and conference call at 2 p.m. PT/5 p.m. ET. Allogene focuses on developing allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease.

### Related Stocks

- [ALLO.US](https://longbridge.com/en/quote/ALLO.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [LABD.US](https://longbridge.com/en/quote/LABD.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

- [Canaccord Genuity Remains a Buy on Allogene Therapeutics (ALLO)](https://longbridge.com/en/news/286408124.md)
- [Allogene Therapeutics ends China cell therapy deal with Overland](https://longbridge.com/en/news/286317303.md)
- [Key facts: Allogene ends Overland license; ALPHA3 58.3% MRD‑negativity](https://longbridge.com/en/news/286380061.md)
- [Allogene Therapeutics - Enters Termination Agreement With Overland Therapeutics On May 12, 2026 - SEC Filing](https://longbridge.com/en/news/286315271.md)
- [08:00 ETAvance Clinical Receives Frost & Sullivan's 2026 Global Company of the Year Recognition for Excellence in Biotech CRO Leadership](https://longbridge.com/en/news/286094661.md)